SCHEMBL3152177

SCHEMBL3152177

CCOC(=O)c1[nH]c(C)cc1CC(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
POLB P06746 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 3/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 6/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
ATM Q13315 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
HPGD P15428 2/20 0.41
GAA P10253 4/20 0.40
MAPT P10636 4/20 0.40
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALOX15 P16050 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11649989 0.85 ALDH1A1 (0.51) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL5085234 0.79 ALDH1A1 (0.46) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL11646638 0.77 CYP4F2 (0.48) ALDH1A1SMN1; SMN2MAPK1LMNAKDM4E
SCHEMBL1681378 0.77 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL257250 0.76 ALDH1A1 (0.62) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL3146885 0.75 ALDH1A1 (0.45) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL11133648 0.75 KDM4E (0.63) ALDH1A1SMN1; SMN2LMNAKDM4ECYP1A2
SCHEMBL3109837 0.73 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2LMNAKDM4ECYP1A2
SCHEMBL31386699 0.73 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2MAPK1LMNA
SCHEMBL16240346 0.71 LMNA (0.42) ALDH1A1MAPK1LMNAKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420810-B2 Bicyclic heterocyclic compound Ono Pharmaceutical, Co., Ltd. (JP) 2013-04-16 US disclosed
US-20100137318-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-03 US disclosed
EP-2154139-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2010-02-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137318-A1 BICYCLIC HETEROCYCLIC COMPOUND CRH, CRHR1, NR3C2 ALDH1A1 1435/4885POLB 3222/4885SMN1; SMN2 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.